Skip to content

Regenerative Medicine & Immunotherapy

Research Summary

At VIC, we aim to develop innovative strategies that harness key components of the immune system to address some of the most pressing challenges in diabetes, neurotrauma, and neurodegenerative disease.

Our team is in active dialog with the Food and Drug Administration (FDA) regarding clinical testing of B cell immunotherapies. We have also initiated pilot preclinical studies with human stem cell-derived islets for type 1 diabetes treatment in non-human primates.

we employ the following strategies for tissue regeneration and immunotherapy:

  • Immunoprotection and regeneration of endogenous pancreatic beta cells
  • Human stem-cell derived islet transplantation without systemic immune-suppresion for type 1 diabetes
  • B cell immunotherapy for accelerating the healing of chronic wounds in diabetes
  • B cell immunotherapy for neuroprotection in traumatic brain injury and neurodegenerative disease

Regenerative medicine & immunotherapy pipeline

1 : Initial R&D

2 : Preclinical Efficacy

3 : Preclinical Safety

4 : Initial Human Studies

Highlighted Publications

Wound Repair Regen. 2017 Sep;25(5):774-791 PMID: 28922523
Sîrbulescu RF, Boehm CK, Soon E, Wilks MQ, Ilieş I, Yuan H, Maxner B, Chronos N, Kaittanis C, Normandin MD, El Fakhri G, Orgill DP, Sluder AE, Poznansky MC

Am J Transplant. 2019 Feb 12. doi: 10.1111/ajt.15308. PMID:30748094
Alagpulinsa DA, Cao JJL, Driscoll K, Sirbulescu RF, Penson MFE, Sremac M, Engquist EN, Brauns T, Markmann JF, Melton DA and Poznansky MC.

explore these labs for more info